Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
May 2022
Historique:
received: 25 10 2021
accepted: 10 01 2022
pubmed: 4 3 2022
medline: 24 5 2022
entrez: 3 3 2022
Statut: ppublish

Résumé

Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a chronic, clinically heterogenous fibroinflammatory condition, characterised by an accumulation of IgG4 secreting plasma cells in affected tissues and associated with increased serum IgG4 concentrations. Despite a growing recognition of the disease among clinicians from different specialties worldwide, its indolent nature, lack of a single diagnostic test and ability to mimic other malignant, infective and inflammatory conditions, makes the diagnosis challenging. As treatment options evolve, biomarkers correlating with disease activity, predicting prognosis and response to treatment are deemed required. A multidisciplinary panel of experts from the European Reference Network for Rare and Complex Connective tissue diseases (ERN ReCONNET) and affiliated international partners have performed a narrative literature search and reviewed the current evidence of biomarkers in IgG4-RD, including immunoglobulins, cytokines, chemokines and other soluble immune mediators, and cellular components of the immune system. The aim of this paper is to provide useful information for clinicians as to the utility of biomarkers for diagnosing and monitoring IgG4-RD in clinical routine and sets out recommendations for clinical decision making.

Identifiants

pubmed: 35238758
doi: 10.55563/clinexprheumatol/qq9qup
pii: 18043
doi:

Substances chimiques

Biomarkers 0
Chemokines 0
Immunoglobulin G 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

71-80

Auteurs

Luca Iaccarino (L)

Rheumatology Unit, Department of Medicine-DIMED, University Hospital of Padua, Italy.

Rosaria Talarico (R)

Rheumatology Unit, AOU Pisana, Pisa, Italy.

Emanuele Bozzalla-Cassione (E)

Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation and University of Pavia, Italy.

Gerd R Burmester (GR)

Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and the Berlin Institute of Health (BIH), Berlin, Germany.

Emma L Culver (EL)

Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.

Andrea Doria (A)

Rheumatology Unit, Department of Medicine-DIMED, University Hospital of Padua, Italy.

Mikael Ebbo (M)

Department of Internal Medicine, Hôpital de la Timone, AP-HM, Aix-Marseille Université, Marseille, France.

P Martin van Hagen (PM)

Departments of Internal Medicine and Immunology, Section Clinical Immunology, Erasmus MC, Rotterdam, the Netherlands.

Eric Hachulla (E)

Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Systémiques et Auto-Immunes Rares du Nord-Ouest (CERAINO), LIRIC, INSERM, Université de Lille, CHU Lille, France.

Jan A M van Laar (JAM)

Departments of Internal Medicine and Immunology, Section Clinical Immunology, Erasmus MC, Rotterdam, the Netherlands.

Marco Lanzillotta (M)

Università Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, and Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Fernando Martinez-Valle (F)

Systemic Autoimmune Diseases Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Spain.

Carlomaurizio Montecucco (C)

Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation and University of Pavia, Italy.

Sara Monti (S)

Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation and University of Pavia, Italy.

Cecilia Nalli (C)

Rheumatology and Immunology Unit, Spedali Civili and University of Brescia, ASST Spedali Civili of Brescia, Italy.

Nicolas Schleinitz (N)

Department of Internal Medicine, Hôpital de la Timone, AP-HM, Aix-Marseille Université, Marseille, France.

Angela Tincani (A)

Rheumatology and Immunology Unit, Spedali Civili and University of Brescia, ASST Spedali Civili of Brescia, Italy.

Emanuel Della-Torre (E)

Università Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, and Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Tobias Alexander (T)

Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and the Berlin Institute of Health (BIH), Berlin, and Deutsches Rheuma-Forschungszentrum (DRFZ Berlin) - a Leibniz Institute, Autoimmunology Group, Berlin, Germany. tobias.alexander@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH